Edition:
India

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

2.56USD
19 Jan 2018
Change (% chg)

$0.06 (+2.40%)
Prev Close
$2.50
Open
$2.48
Day's High
$2.60
Day's Low
$2.43
Volume
7,753
Avg. Vol
17,671
52-wk High
$3.12
52-wk Low
$1.45

Chart for

About

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue... (more)

Overall

Beta: --
Market Cap(Mil.): $49.25
Shares Outstanding(Mil.): 22.49
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan

* HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET

21 Dec 2017

BRIEF-MEDINET signs license contract for NeoCart with Histogenics

* Says it entered into a license contract for development and sale of autologous cultured chondrocyte named NeoCart, with Histogenics Corp

21 Dec 2017

BRIEF-Histogenics Corp announces Q3 loss per share $0.23

* Histogenics Corporation announces third quarter 2017 financial and operating results

09 Nov 2017

BRIEF-Histogenics Corp promotes Stephen Kennedy to COO

* Histogenics Corporation promotes Stephen Kennedy to executive vice president & chief operating officer Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-Histogenics says Q2 loss per share $0.25

* Histogenics corporation announces second quarter 2017 financial and operating results

10 Aug 2017

Earnings vs. Estimates